Difference between revisions of "Radotinib (Supect)"
Jump to navigation
Jump to search
m (Jwarner moved page Radotinib (IY5511HCL) to Radotinib (Supect)) |
m |
||
| Line 2: | Line 2: | ||
Selective BCR-ABL1 tyrosine kinase inhibitor | Selective BCR-ABL1 tyrosine kinase inhibitor | ||
| − | [[Category: | + | ==Preliminary data== |
| + | ===[[Chronic myelogenous leukemia]]=== | ||
| + | # Kim SH, Menon H, Jootar S, Saikia T, Kwak JY, Sohn SK, Park JS, Jeong SH, Kim HJ, Kim YK, Oh SJ, Kim H, Zang DY, Chung JS, Shin HJ, Do YR, Kim JA, Kim DY, Choi CW, Park S, Park HL, Lee GY, Cho DJ, Shin JS, Kim DW. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Haematologica. 2014 Jul;99(7):1191-6. Epub 2014 Apr 4. [http://www.haematologica.org/content/99/7/1191.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/24705186 PubMed] | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Oral chemotherapy]] | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
| Line 8: | Line 14: | ||
[[Category:Chronic myelogenous leukemia medications]] | [[Category:Chronic myelogenous leukemia medications]] | ||
| + | |||
| + | [[Category:Investigational]] | ||
Revision as of 02:56, 16 November 2014
Mechanism of action
Selective BCR-ABL1 tyrosine kinase inhibitor
Preliminary data
Chronic myelogenous leukemia
- Kim SH, Menon H, Jootar S, Saikia T, Kwak JY, Sohn SK, Park JS, Jeong SH, Kim HJ, Kim YK, Oh SJ, Kim H, Zang DY, Chung JS, Shin HJ, Do YR, Kim JA, Kim DY, Choi CW, Park S, Park HL, Lee GY, Cho DJ, Shin JS, Kim DW. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Haematologica. 2014 Jul;99(7):1191-6. Epub 2014 Apr 4. link to original article PubMed